Does Georgia’s learned-intermediary rule affect my defective-drug warning claim?
Yes. The learned-intermediary doctrine directly shapes how a failure-to-warn claim against a prescription-drug maker works in Georgia. It changes who the manufacturer must warn and, in turn, what an injured person has to prove to show that an inadequate warning caused harm.
Who the manufacturer must warn ¶
Under the learned-intermediary rule, a maker of a prescription drug generally satisfies its duty to warn by adequately warning the prescribing physician, not the patient directly. The reasoning is that the physician is the trained professional who weighs the drug’s risks and benefits for a particular patient and decides whether to prescribe it. The doctor sits between the manufacturer and the patient as the informed decision-maker, so the law channels the warning duty through that relationship. This means a manufacturer is not ordinarily required to communicate risk information straight to the consumer.
How it changes the causation question ¶
The doctrine’s biggest practical effect is on causation in a warning claim. Because the duty runs to the physician, an injured person generally must show that a different or better warning would have changed the prescribing physician’s decision. If the physician already knew of the risk, or would have prescribed the drug regardless, the inadequate warning may not be the cause of the injury. As a result, the prescribing physician’s knowledge and testimony often become central evidence. Key issues commonly include:
- What the physician already understood about the relevant risk.
- Whether an improved warning would have altered the decision to prescribe.
- Whether the physician’s independent judgment, rather than the warning, drove the outcome.
Scope and limits ¶
The rule applies to the manufacturer’s warning obligation in the prescription-drug context. It does not, by itself, defeat other theories such as a defectively designed or contaminated drug, which rest on different proof. It also does not eliminate the requirement to show that the drug actually caused the injury, which remains a separate medical-causation question. And regardless of how the warning issue plays out, the suit must be brought within the two-year personal-injury limit in O.C.G.A. § 9-3-33.
The bottom line ¶
Georgia’s learned-intermediary rule reshapes a defective-drug warning claim by directing the manufacturer’s duty to warn at the prescribing physician rather than the patient. The main consequence is that causation hinges on whether a better warning would have changed the physician’s prescribing decision, making the doctor’s knowledge and testimony pivotal, while other defect theories and the underlying causation requirement remain in play.
This article is for general educational and informational purposes only and is not legal advice. It does not create an attorney-client relationship, and Georgia law may change. For advice about a specific situation, consult a licensed Georgia personal injury attorney.